{"entity":{"id":"nct07209813","kind":"trial","name":"GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma","aka":[],"tldr":"A phase 2 trial of GKL-006 Injection in hepatocellular carcinoma, run by Beijing Gene Key Life Technology Co., Ltd, now recruiting.","summary":"GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT07209813 by Beijing Gene Key Life Technology Co., Ltd, with 48 participants planned, started 2025-11-14 and due to reach its primary completion in 2027-09-30. Interventions recorded: GKL-006 Injection and TACE.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07209813","url":"https://clinicaltrials.gov/study/NCT07209813"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07209813","phase":"2","setting":"A Multicenter, Randomized, Open-Label, Controlled Phase 2 Study of GKL-006 Injection in Combination With Transarterial Chemoembolization (TACE) Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma","sponsor":"Beijing Gene Key Life Technology Co., Ltd","enrolled":48,"outcomes":[]},"route":"/trials/nct07209813/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"company":[{"id":"beijing-gene-key-life-technology","kind":"company","name":"Beijing Gene Key Life Technology","route":"/companies/beijing-gene-key-life-technology/"}]}}